Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Betamethasone 0.05%/Doxycycline 10%/Nystatin 2% m/wash sach
1203010W0AAAAAA
|
Betamethasone/Doxycyline/Nystatin | Betamethasone/Doxycycline/Nystatin | Ear, Nose and Oropharynx | 3 |
|
Betamethasone valerate 0.1% oint 50% in White soft paraffin
1304000F0AACZCZ
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 3 |
|
Biatain Ag dressing 18cm x 18cm square
20030600281
|
Biatain Ag dressing 18cm x 18cm square | Wound Management & Other Dressings | Dressings | 3 |
|
BiCarb-500 capsules
0902013S0BEAAAC
|
BiCarb (Supplements) | Sodium bicarbonate | Nutrition and Blood | 3 |
|
Bioclusive Plus dressing 20cm x 30cm
20030100189
|
Bioclusive Plus dressing 20cm x 30cm | Wound Management & Other Dressings | Dressings | 3 |
|
Biosorb Gelling Fibre dressing 15cm x 15cm square
20031700255
|
Biosorb Gelling Fibre dressing 15cm x 15cm square | Wound Management & Other Dressings | Dressings | 3 |
|
Bioteque America gellhorn pessary size 7, 83mm diameter, silicone, standard stem
21011200358
|
Bioteque America gellhorn pessary size 7, 83mm diameter, silicone, standard stem | Other Appliances | Appliances | 3 |
|
Birkbeck rubber ileostomy day bag 19mm black
23601256215
|
Birkbeck rubber ileostomy day bag 19mm black | Ileostomy Bags | Stoma Appliances | 3 |
|
Bisoprolol 7.5mg/5ml oral liquid
0204000H0AABBBB
|
Bisoprolol fumarate | Bisoprolol fumarate | Cardiovascular System | 3 |
|
Blistex Relief cream
131003000BLBJA0
|
Proprietary compound preparation BNF 1310030 | Other antiviral preparations | Skin | 3 |
|
Blom-Singer TruSeal baseplate
20050300167
|
Blom-Singer TruSeal baseplate | Tracheostomy & Laryngectomy Appliances | Dressings | 3 |
|
Botox 100unit powder for solution for injection vials
0409030B0BCAAAE
|
Botox | Botulinum toxin type A | Central Nervous System | 3 |
|
Brodilaten 2.5mg/2.5ml nebuliser solution unit dose ampoules
0301011R0CBACCD
|
Brodilaten | Salbutamol | Respiratory System | 3 |
|
buddy limb protector leg short small aperture size 30mm
21011300140
|
buddy limb protector leg short small aperture size 30mm | Other Appliances | Appliances | 3 |
|
Budesonide 1mg/2ml nebuliser suspension unit dose ampoules
0302000K0AABEBE
|
Budesonide (Inhalation) | Budesonide | Respiratory System | 3 |
|
Buplast 35micrograms/hour transdermal patches
0407020B0BNAAAE
|
Buplast | Buprenorphine | Central Nervous System | 3 |
|
Buprenorphine 32mg/0.64ml prolonged-release inj pfs
0410030A0AAARAR
|
Buprenorphine (Opioid Dependance) | Buprenorphine hydrochloride | Central Nervous System | 3 |
|
Buspirone 5mg/5ml oral suspension
0401020B0AAAGAG
|
Buspirone hydrochloride | Buspirone hydrochloride | Central Nervous System | 3 |
|
Busulfan 2mg tablets
0801010B0AAABAB
|
Busulfan | Busulfan | Malignant Disease and Immunosuppression | 3 |
|
C-Foam Silicone dressing 10cm x 10cm
20030900327
|
C-Foam Silicone dressing 10cm x 10cm | Wound Management & Other Dressings | Dressings | 3 |
|
C-Foam Silicone dressing 10cm x 20cm
20030900328
|
C-Foam Silicone dressing 10cm x 20cm | Wound Management & Other Dressings | Dressings | 3 |
|
Caffeine citrate 50mg/5ml oral solution
0404000E0AAAKAK
|
Caffeine citrate | Caffeine citrate | Central Nervous System | 3 |
|
Calamine and Coal tar ointment
1305020C0AAACAC
|
Coal tar/tar (Topical) | Tars | Skin | 3 |
|
Camphor 3.57%/Salicylic acid 3.57%/Phenol 2.85%/Sulfur 2.14%
130900000AABGBG
|
Generic compound preparation BNF 1309000 | Other shampoo and scalp preparations | Skin | 3 |
|
Carbimazole 2mg/5ml oral liquid
0602020D0AAAUAU
|
Carbimazole | Carbimazole | Endocrine System | 3 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.